- Category: HIV Prevention
- Published on Wednesday, 17 December 2014 00:00
- Written by CDC
The U.S. Centers for Disease Control and Prevention (CDC), in collaboration with several government, professional, and non-profit organizations, last week issued updated recommendations about biomedical, behavioral, and structural interventions to help people with HIV reduce the risk of onward transmission of the virus.
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 10 December 2014 00:00
- Written by Liz Highleyman
No new HIV infections have occurred among more than 500 Kaiser Permanente San Francisco members using pre-exposure prophylaxis -- better known as PrEP -- but condom use appears to be declining among a subset of gay men, according to a small survey presented at a December 1 forum commemorating World AIDS Day.
- Category: HIV Vaccines
- Published on Wednesday, 19 November 2014 00:00
- Written by Gus Cairns
Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P) in Cape Town. They showed evidence of stronger antibody responses, and in-depth analysis of these responses suggests that by further developing a similar vaccine, it may be possible to push the immune system to generate an antibody response to HIV that is sufficiently strong to prevent most infections.
- Category: HIV Sexual Transmission
- Published on Tuesday, 09 December 2014 00:00
- Written by Gladstone Institutes
A component in semen appears to increase the likelihood of sexual transmission of HIV, and furthermore may enable the virus to over-power topical microbicides designed to prevent infection, according to a study published in the November 12 edition of Science Translational Medicine. This may be one of the factors explaining why drugs that block HIV infection in laboratory experiments have not worked in real-world settings, the researchers suggested.
- Category: HIV Vaccines
- Published on Monday, 10 November 2014 00:00
- Written by Craig Rouskey
Microparticles containing conserved HIV epitopes may be able to prime antigen-presenting dendritic cells, which in turn activate antigen-specific CD8 killer T-cells, offering a potential new approach for developing T-cell-based preventive or therapeutic HIV vaccines, researchers with the open-access Immunity Project reported at the HIV Research for Prevention (HIV R4P) conference last week in Cape Town.